Korea We are actively seeking opportunities to export our medicines to markets around the world Jae-young Lee took the helm of Bukwang Pharmaceuticals in 2024, inheriting a business undergoing serious challenges and with little room for complacency. Two years on, the company is back in profit, pursuing an ambitious growth target…
Korea Several medicines available in the US today have Korean origins, but few are commercialised by Korean companies directly. Instead, most Korean pharmas and biotechs with innovative portfolios have chosen to out-license their molecules, with Western companies signing licensing deals worth up to USD 23.3 billion for Korean-developed medicines in the…
Korea Dr Jai Jun Choung, CEO of AriBio, discusses the company’s integrated approach to neurodegenerative disease, combining AI-driven network biology, polypharmacology and prevention to develop therapies for Alzheimer’s and related disorders. He outlines the progress of lead candidate AR1001, the broader pipeline, strategic partnerships, and Korea’s biotech ecosystem, while emphasising patient-centred…
USA Neuroscience is back. Scientific breakthroughs have created new tools and approaches, investment in diseases of the brain is up, and regulators are approving drugs in therapeutic areas that have been static for decades. Neuroscience researchers have a better technological toolset available to them than ever before. Genetics and biomarkers have…
Saudi Arabia Mostafa Abdelrahman, General Manager of Lilly Saudi Arabia, discusses the company’s evolution from medicine supplier to healthcare partner, supporting Vision 2030 through innovation, public-private collaboration and localisation. He highlights advances in obesity, Alzheimer’s disease and oncology, alongside technology transfer, clinical research and talent development, while outlining priorities to expand patient…
Taiwan A genuinely healthy lifestyle can help prevent neurodegenerative disease Charles S.Y. Yang discusses how his background in physics and quantum sensing led to the founding of MagQu, pioneering ultra-sensitive blood biomarker diagnostics for Alzheimer’s and other neurodegenerative diseases. He explains the company’s SQUID-based technology, commercial journey, regulatory ambitions and funding…
China Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord injury, MSA and ALS have remained among the most difficult conditions to treat, with available therapies largely focused on managing…
Germany Transformation often reveals itself not through grand declarations, but through the decisions organisations make about where to invest, what capabilities to build, and how they choose to serve patients. At Angelini Pharma Germany, that evolution is taking shape through a growing commitment to Brain Health, a resilient Consumer Health business,…
France France Alzheimer’s Joel Jaouen and Benoit Durand articulate a comprehensive strategic framework for addressing one of Europe’s most pressing healthcare challenges. With four decades of operational excellence, the organisation has evolved from a grassroots family initiative into France’s premier associative research funder, developing sophisticated care pathways whilst advocating for systemic…
USA Neurvati Neurosciences is carving a distinctive path in one of medicine’s most high-risk arenas: neuroscience. In this interview, President and CEO Dr Bruce Leuchter explains how a private equity-inspired model, backed by Blackstone Life Sciences, is enabling the company to advance late-stage assets, forge global partnerships, and build a values-driven…
Global As neuroscience reclaims a place at the top table of pharmaceutical innovation, Bristol Myers Squibb (BMS) is quietly reshaping its presence in the field. Spearheaded by its Neuroscience Thematic Research Center, the company is pursuing a dual mandate: to slow the progression of diseases like Alzheimer’s while also addressing their…
Denmark Ian Laquian’s journey from Big Pharma strategy leadership to entrepreneurial venture creation exemplifies the innovative thinking required to address intractable neurological challenges. Having spearheaded CNS therapeutic area strategy at Takeda Pharmaceuticals, Laquian has pioneered a ground-breaking approach that leverages metabolic pathways to treat neurodegenerative diseases. Through the establishment of Kariya…
See our Cookie Privacy Policy Here